Lysine as a prophylactic agent in the treatment of recurrent herpes simplex labialis

Thein, D.J.; Hurt, William C.

doi:10.1016/0030-4220(84)90030-6

Cited by 35 publications

(27 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Improved designs with randomized assignment of patients to treatment and control groups were used in subsequent clinical investigations, which provided both negative and positive findings. Overall, though results were quite variable, there were more reports of fair to good efficacy, especially in prophylaxis, than of poor or no efficacy [66,67].…”

Section: Pharmacology Recurrent Herpes Simplexmentioning

confidence: 99%

The metabolic roles, pharmacology, and toxicology of lysine.

Flodin

1997

Journal of the American College of Nutrition

View full text Add to dashboard Cite

L-lysine monohydrochloride (LMH) is widely available to the public as a nonprescription oral supplement. Most of the pharmaceutical-grade product is used as a suppressant of recurrent herpes simplex infections. Recent publications indicate the possibility of other therapeutic uses, e.g., in cardiovascular disease and osteoporosis. These and other potential applications are surveyed and evaluated in this review with suggestions for further study. Data on toxicity are reviewed and recommendations made regarding safety of chronic dosage levels.

show abstract

Section: Pharmacology Recurrent Herpes Simplexmentioning

confidence: 99%

The metabolic roles, pharmacology, and toxicology of lysine.

Flodin

1997

Journal of the American College of Nutrition

View full text Add to dashboard Cite

show abstract

“…Although their data were obtained by a questionnaire method, the study showed oral L-lysine therapy was a preventive meas ure for recurrent HSV infections. Thein and Hunt [10] studied 26 patients with a history of recurrent herpetic lesions. In a ran domized, double-blind, placebo-controlled, crossover study one group took 1,000 mg of L-lysine daily and the other group took placebo.…”

Section: Introductionmentioning

confidence: 99%

Success of <i>L</i>-Lysine Therapy in Frequently Recurrent Herpes simplex Infection

Griffith

Walsh²,

Myrmel³

et al. 1987

Dermatology

View full text Add to dashboard Cite

A double-blind, placebo-controlled, multicenter trial of oral L-lysine monohydrochloride for the prevention and treatment of recurrent herpes simplex (HSV) infection was conducted. The treatment group was given L-Lysine monohydrochloride tablets (1,000 mg L-lysine per dose) 3 times a day for 6 months. A total of 27 (6 male and 21 female) subjects on L-lysine and 25 (6 male and 19 female) subjects on placebo completed the trial. The L-lysine treatment group had an average of 2.4 (p < 0.05) less HSV infections, symptoms were significantly (p < 0.05) diminished in severity and healing time was significantly reduced (p < 0.05). L-Lysine appears to be an effective agent for reduction of occurrence, severity and healing time for recurrent HSV infection.

show abstract

“…Regardless, it remains possible that there is a critical plasma lysine concentration for control of IURD, as has been proposed for humans affected by herpes labialis caused by herpes simplex virus type 1. 20 If so, then it is possible that bolus administration yields an increase in plasma lysine concentration that is higher than this critical concentration more reliably than does dietary supplementation.…”

Section: Discussionmentioning

confidence: 99%